Inhibitors like Lipofermata, which target FATP2 (the protein encoded by SLC27A2), have demonstrated efficacy in other cancers by disrupting fatty acid uptake and inducing apoptosis, illustrating a principle of targeting the protein’s activity regardless of its expression level [36]. The gene discussed is SLC27A2; the disease is cancer.